Erick Gamelin insider trades: Acrivon Therapeutics (ACRV) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Erick reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | ACRV | ↓ Sell | 400 | $2.01 | $804 | Direct | Aug 20, 2026 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ACRV insiders
Open-market trades in the last 12 months
About Erick Gamelin's insider trades
Erick Gamelin is Chief Development Officer at Acrivon Therapeutics (ACRV). Since Aug 18, 2026, Erick has reported no open-market purchases and 1 sale worth $804 on SEC Form 4. In the last 12 months: 1 sale ($804).
Their filings also include shares withheld for taxes (10 filings), grants and awards (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACRV insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.